DexCom stock snapshot and recent performance DexCom (DXCM) has been drawing attention after recent price moves, with the ...

It has had strong momentum since November, but there is still plenty of upside left.

Wondering whether DexCom's current share price lines up with its underlying worth, or if the market is missing something ...

DXCM posts strong preliminary Q4 and full-year 2025 revenue growth, beating estimates, though shares slip after the ...

DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...

DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on BillionToOne, Inc. Class A ( BLLN – Research Report) and Dexcom ( DXCM – Research Report ).

Fintel reports that on January 12, 2026, Barclays downgraded their outlook for DexCom (NasdaqGS:DXCM) from Equal-Weight to ...

DexCom recently reported preliminary, unaudited results showing fourth-quarter 2025 revenue of about US$1.26 billion and full ...